PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)

Completed

Conditions: Smoking Cessation

Interventions: Drug: Varenicline

First Posted Date: 2008-10-15

Last Posted Date: 2014-02-28

Lead Sponsor: Pfizer

Target Recruit Count: 3939

Registration Number: NCT00772941

Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)

Completed

Conditions: Major Depressive Disorder

Interventions: Other: Cohort

First Posted Date: 2008-10-09

Last Posted Date: 2012-08-31

Lead Sponsor: Pfizer

Target Recruit Count: 851

Registration Number: NCT00770289

Locations: 🇬🇷
Pfizer Investigational Site, Ilissia, Athens, Greece

Study Evaluating the Nasopharyngeal Carriage in Healthy Children

Completed

Conditions: Healthy Subjects

First Posted Date: 2008-10-08

Last Posted Date: 2014-08-21

Lead Sponsor: Pfizer

Target Recruit Count: 242

Registration Number: NCT00768833

Locations: 🇩🇪
Pfizer Investigational Site, Offenbach, Germany

Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small Cell Lung

Interventions: Drug: axitinib
Drug: chemotherapy

First Posted Date: 2008-10-08

Last Posted Date: 2015-10-28

Lead Sponsor: Pfizer

Target Recruit Count: 180

Registration Number: NCT00768755

Locations: 🇬🇧
Pfizer Investigational Site, Poole, United Kingdom

Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

Phase 2

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: PF-00299804

First Posted Date: 2008-10-08

Last Posted Date: 2021-02-09

Lead Sponsor: Pfizer

Target Recruit Count: 69

Registration Number: NCT00768664

Locations: 🇨🇦
Hopital Notre-dame du CHUM - Oncology Center, Montreal, Quebec, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

and more 6 locations

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Erlotinib
Drug: PF-00299804

First Posted Date: 2008-10-08

Last Posted Date: 2015-10-07

Lead Sponsor: Pfizer

Target Recruit Count: 188

Registration Number: NCT00769067

Locations: 🇵🇱
Medex spolka cywilna, Chrzanow, Poland
🇪🇸
Hospital de Cruces, Barakaldo, Vizcaya, Spain
🇵🇱
"Vesalius" Sp. z o.o., Krakow, Poland

and more 54 locations

Study Evaluating Microbiological Analysis of Spontaneous Draining Acute Otitis Media

Completed

Conditions: Otitis Media

First Posted Date: 2008-10-08

Last Posted Date: 2016-10-06

Lead Sponsor: Pfizer

Target Recruit Count: 2138

Registration Number: NCT00768534

Locations: 🇩🇪
Dr. Andreas Busse, Tegernsee, Bavarian, Germany

Study Evaluating The Safety Of Xyntha In Usual Care Settings

Phase 4

Terminated

Conditions: Hemophilia A

Interventions: Biological: Moroctocog alfa(AF-CC)
Procedure: Blood draw for laboratory testing

First Posted Date: 2008-10-03

Last Posted Date: 2012-01-20

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00765726

Locations: 🇳🇿
Pfizer Investigational Site, Christchurch, New Zealand

The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)

Phase 2

Completed

Conditions: Diabetic Foot Ulcer

Interventions: Drug: Fragmin

First Posted Date: 2008-10-02

Last Posted Date: 2012-01-13

Lead Sponsor: Pfizer

Target Recruit Count: 62

Registration Number: NCT00765063

Locations: 🇬🇧
Pfizer Investigational Site, Birmingham, United Kingdom

A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: Protopic® Ointment, 0.1 %
Drug: AN2728 Ointment, 2%
Drug: AN2728 Ointment Vehicle
Drug: AN2728 Ointment, 0.5%
Drug: Betnesol®-V Creme, 0.1%
Drug: AN2728 Ointment, 5%

First Posted Date: 2008-09-30

Last Posted Date: 2019-02-22

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00762658

Locations: 🇩🇪
Bioskin GmbH, Hamburg, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy